Stein RE, et al. - Here, the researchers assessed the use of iron sucrose in pediatric inflammatory bowel disease (IBD) subjects with iron deficiency anemia (IDA) and determine the clinical response as measured by improvement in hemoglobin concentration. They further described adverse events associated with iron sucrose use in this cohort. In pediatric IBD, intravenous iron sucrose was found to be a safe and potentially efficacious treatment choice for IDA. They reported 18 adverse events in 13 subjects (18.1% of subjects and 6.6% of infusions). No anaphylaxis reactions occurred and none of the adverse events were, however, life-threatening or required hospitalization.